These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 31211217)

  • 21. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.
    Langbaum JB; Hendrix SB; Ayutyanont N; Chen K; Fleisher AS; Shah RC; Barnes LL; Bennett DA; Tariot PN; Reiman EM
    Alzheimers Dement; 2014 Nov; 10(6):666-74. PubMed ID: 24751827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
    Burns DK; Alexander RC; Welsh-Bohmer KA; Culp M; Chiang C; O'Neil J; Evans RM; Harrigan P; Plassman BL; Burke JR; Wu J; Lutz MW; Haneline S; Schwarz AJ; Schneider LS; Yaffe K; Saunders AM; Ratti E;
    Lancet Neurol; 2021 Jul; 20(7):537-547. PubMed ID: 34146512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.
    Egan MF; Kost J; Voss T; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; van Dyck CH; Boada M; Zhang Y; Li W; Furtek C; Mahoney E; Harper Mozley L; Mo Y; Sur C; Michelson D
    N Engl J Med; 2019 Apr; 380(15):1408-1420. PubMed ID: 30970186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease - Study Protocol and Baseline Characteristics.
    Snellman A; Ekblad LL; Koivumäki M; Lindgrén N; Tuisku J; Perälä M; Kallio L; Lehtonen R; Saunavaara V; Saunavaara J; Oikonen V; Aarnio R; Löyttyniemi E; Parkkola R; Karrasch M; Zetterberg H; Blennow K; Rinne JO
    Front Neurol; 2022; 13():826423. PubMed ID: 35222254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
    Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
    Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease.
    Farlow MR; Andreasen N; Riviere ME; Vostiar I; Vitaliti A; Sovago J; Caputo A; Winblad B; Graf A
    Alzheimers Res Ther; 2015; 7(1):23. PubMed ID: 25918556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set.
    Puzo C; Labriola C; Sugarman MA; Tripodis Y; Martin B; Palmisano JN; Steinberg EG; Stein TD; Kowall NW; McKee AC; Mez J; Killiany RJ; Stern RA; Alosco ML
    Alzheimers Res Ther; 2019 Jul; 11(1):64. PubMed ID: 31351489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
    Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M
    J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuropathology-based APOE genetic risk score better quantifies Alzheimer's risk.
    Deming Y; Vasiljevic E; Morrow A; Miao J; Van Hulle C; Jonaitis E; Ma Y; Whitenack V; Kollmorgen G; Wild N; Suridjan I; Shaw LM; Asthana S; Carlsson CM; Johnson SC; Zetterberg H; Blennow K; Bendlin BB; Lu Q; Engelman CD;
    Alzheimers Dement; 2023 Aug; 19(8):3406-3416. PubMed ID: 36795776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.
    Lowe VJ; Wiste HJ; Senjem ML; Weigand SD; Therneau TM; Boeve BF; Josephs KA; Fang P; Pandey MK; Murray ME; Kantarci K; Jones DT; Vemuri P; Graff-Radford J; Schwarz CG; Machulda MM; Mielke MM; Roberts RO; Knopman DS; Petersen RC; Jack CR
    Brain; 2018 Jan; 141(1):271-287. PubMed ID: 29228201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
    Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
    Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
    Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
    Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
    Femminella GD; Frangou E; Love SB; Busza G; Holmes C; Ritchie C; Lawrence R; McFarlane B; Tadros G; Ridha BH; Bannister C; Walker Z; Archer H; Coulthard E; Underwood BR; Prasanna A; Koranteng P; Karim S; Junaid K; McGuinness B; Nilforooshan R; Macharouthu A; Donaldson A; Thacker S; Russell G; Malik N; Mate V; Knight L; Kshemendran S; Harrison J; Hölscher C; Brooks DJ; Passmore AP; Ballard C; Edison P
    Trials; 2019 Apr; 20(1):191. PubMed ID: 30944040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amyloid-β Positivity Predicts Cognitive Decline but Cognition Predicts Progression to Amyloid-β Positivity.
    Elman JA; Panizzon MS; Gustavson DE; Franz CE; Sanderson-Cimino ME; Lyons MJ; Kremen WS;
    Biol Psychiatry; 2020 May; 87(9):819-828. PubMed ID: 32067693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.